[HTML][HTML] Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease
A Floch, A Morel, F Zanchetta-Balint… - …, 2020 - ncbi.nlm.nih.gov
Delayed hemolytic transfusion reaction (DHTR) is an unpredictable severe complication of
transfusion in patients with sickle cell disease (SCD). It presents clinically as a vaso …
transfusion in patients with sickle cell disease (SCD). It presents clinically as a vaso …
Management of Hyperhemolysis in β-Thalassemia with Complement Blockade
R Zanetti, L Vasta, K Romanelli, T Newton - Authorea Preprints, 2020 - essopenarchive.org
Introduction: Hyperhemolysis is a life-threatening condition of exaggerated hemolysis of red
blood cells which occurs in patients receiving chronic transfusion therapy. Results: We …
blood cells which occurs in patients receiving chronic transfusion therapy. Results: We …
Long term Use of Eculizumab for Delayed Hemolytic Transfusion Reaction in Pediatric Sickle Cell: A Case Report
C Noda - Authorea Preprints, 2020 - essopenarchive.org
Compliment activation has been implicated in Delayed Hemolytic Transfusion Reaction
(DHTR) in patients with sickle cell disease, and eculizumab has been reported as an …
(DHTR) in patients with sickle cell disease, and eculizumab has been reported as an …